HEALTH AND HUMAN SERVICES, DEPARTMENT OF
- Posted
- Oct 9, 2026
- Due
- Oct 16, 2026, 12:00 PM EDT
- Place of performance
- Bethesda, MD
- NAICS
- 334516
- Set-aside
- No Set Aside
Special NoticeActive
Intent to Sole Source - Medical/Scientific Instruments for the Department of Transfusion Medicine, NIH Clinical Center
HEALTH AND HUMAN SERVICES, DEPARTMENT OF · NATIONAL INSTITUTES OF HEALTH
Contract Details
- Notice ID
- NOI-OLAO-CC-27-000121
- Opportunity Type
- Special Notice
- Sub-Agency
- NATIONAL INSTITUTES OF HEALTH
- Office
- NATIONAL INSTITUTES OF HEALTH
- Posted Date
- Thursday, October 8, 2026
- Response Deadline
- Oct 23, 2026, 12:00 PM EDT
- PSC Code
- 6640
- Set-Aside
- No Set Aside
- Place of Performance
- Bethesda, MD, 20892, USA
- Status
- Active
Description
This is a Notice of Intent, not a request for proposal. The National Institute of Health, Clinical Center (NIH-CC) intends to negotiate on an other than full and open competition basis with the following vendor: Fisher Scientific. Acquisition Description: The NIH Clinical Center, Department of Transfusion Medicine (DTM), Infectious Diseases Section requires acquisition of a 1) Real-Time PCR System, 2) an Automated Nucleic Acid Extractor and 3) a microvolume spectrophotometer to support clinical research and the development, optimization, and validation of diagnostic assays for hepatitis viruses and other transfusion-transmitted pathogens. The required system must support generation of high-quality quantification data from clinical specimens, including viral RNA/DNA and host-derived nucleic acids. The instrument must enable applications such as targeted genome amplification, work with a wider dynamic detection range, support the library prep for viral genome sequencing, and assay development workflows necessary for evaluating test performance and refining diagnostic methods prior to implementation in a clinical testing environment. The system must meet the following functional and operational requirements: High data accuracy and reproducibility to ensure reliable detection of viral variants and evaluation of assay performance; Low- to moderate-throughput capability appropriate for assay development, pilot studies, and validation activities involving smaller sample sets; Rapid turnaround times to support iterative testing and optimization of clinical assays; Flexible run configurations that allow efficient processing of varying sample volumes without excess capacity; Cost-efficient operation, including the ability to minimize per-run and per-sample costs for pathogen dete
Read full description (3,044 characters)
ction; Integrated and streamlined workflows, including nucleic acid extraction, amplification, quantification and data analysis within a platform from the same vendor to reduce complexity and variability; Ease of use and standardized operation, supporting reproducibility and implementation in a clinical laboratory environment; Compatibility with established nucleic acid preparation and amplification methods and existing laboratory workflows. The flexibility to be using the systems in a CLIA certified environment. The statutory authority for this sole source requirement is 41 U.S.C. 253(c) (1) as implemented by FAR 6.302-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide the required may submit a capability statement that will be considered by email (subject line to reference NOI-OLAO-CC-27-000121) by 12:00 PM eastern standard time on 10/23/2026 to: valerie.gregorio@nih.gov. All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.
Documents and contact
No public document links were provided with this record.
Check the official notice for attachments and access requirements ↗
Loadingchange history…
Loadingrelated notices…